{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:12:12Z","timestamp":1790694732497,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["NIHR135447"],"award-info":[{"award-number":["NIHR135447"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s40273-023-01259-6","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T11:04:46Z","timestamp":1679569486000},"page":"741-750","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7473-7318","authenticated-orcid":false,"given":"Giovany","family":"Orozco Leal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7443-4798","authenticated-orcid":false,"given":"Nigel","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5514-3186","authenticated-orcid":false,"given":"Ashleigh","family":"Kernohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6420-9071","authenticated-orcid":false,"given":"Charlotte","family":"Ahmadu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5348-3750","authenticated-orcid":false,"given":"Diarmuid","family":"Coughlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9415-8647","authenticated-orcid":false,"given":"Kevin","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7335-8167","authenticated-orcid":false,"given":"Steven","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3448-2234","authenticated-orcid":false,"given":"Susan","family":"O\u2019Meara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8695-9738","authenticated-orcid":false,"given":"Tomos","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8574-8429","authenticated-orcid":false,"given":"Luke","family":"Vale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos","family":"Kleijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"1259_CR1","volume-title":"Abemaciclib in combination with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer [ID3857]","author":"N Armstrong","year":"2022","unstructured":"Armstrong N, Vale L, Coughlan D, Orozco Leal G, Robinson T, Kernohan A, et al. Abemaciclib in combination with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer [ID3857]. York: Kleijnen Systematic Reviews Ltd; 2022."},{"key":"1259_CR2","unstructured":"National Institute for Health and Care Excellence. Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence (review of TA810) [ID3857]: Committee Papers. 2022. https:\/\/www.nice.org.uk\/guidance\/ta810\/evidence. Accessed 11 Jan 2023"},{"key":"1259_CR3","unstructured":"Eli Lilly and Company Limited. Abemaciclib for adjuvant treatment of hormone receptor positive, HER2-negative, node-positive early breast cancer [ID3857]. Document B. Company evidence submission. Single technology appraisal (STA). Eli Lilly and Company Limited; 2021."},{"issue":"34","key":"1259_CR4","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987\u201398.","journal-title":"J Clin Oncol"},{"key":"1259_CR5","unstructured":"ClinicalTrials.gov. Endocrine therapy with or withoutabemaciclib (LY2835219) following surgery in participants with breast cancer (monarchE). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03155997. Accessed 11 Jan 2023."},{"key":"1259_CR6","unstructured":"National Institute for Health and Care Excellence. Early and locally advanced breast cancer: diagnosis and management. NICE guideline 101. 2018. https:\/\/www.nice.org.uk\/guidance\/ng101. Accessed 11 Jan 2023."},{"key":"1259_CR7","unstructured":"Eli Lilly and Company Limited. Abemaciclib in combination with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer [ID3857]. Clarification questions. Eli Lilly and Company Limited; 2021."},{"key":"1259_CR8","volume-title":"Microsoft Excel","author":"M Corporation","year":"2018","unstructured":"Corporation M. Microsoft Excel. Redmond: Microsoft Corporation; 2018."},{"key":"1259_CR9","unstructured":"Latimer N. NICE DSU Technical Support Document 14: Undertaking survival analysis for economic evaluations alongside clinical trials\u2014extrapolation with patient-level data. 2011. http:\/\/www.nicedsu.org.uk. Accessed 11 Jan 2023."},{"issue":"12","key":"1259_CR10","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","volume":"11","author":"J Cuzick","year":"2010","unstructured":"Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135\u201341.","journal-title":"Lancet Oncol"},{"key":"1259_CR11","unstructured":"National Institute for Health and Care Excellence. Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2- positive early stage breast cancer after adjuvant trastuzumab. Technology appraisal guidance 612. 2019. https:\/\/www.nice.org.uk\/guidance\/TA612. Accessed 11 Jan 2023."},{"key":"1259_CR12","unstructured":"National life tables: UK. Office for National Statistics. 2021. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/datasets\/nationallifetablesunitedkingdomreferencetables. Accessed 11 Jan 2023."},{"key":"1259_CR13","unstructured":"National Institute for Health and Care Excellence. Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer. Technology appraisal guidance 632. 2020. https:\/\/www.nice.org.uk\/guidance\/TA632. Accessed 21 Dec 2022."},{"key":"1259_CR14","unstructured":"National Institute for Health and Care Excellence. Abemaciclib with an aromatase inhibitor for untreated advanced hormone-receptor positive, HER2-negative breast cancer ID1227. Technology appraisal guidance TA563. 2019. https:\/\/www.nice.org.uk\/guidance\/TA563. Accessed 21 Dec 2022."},{"key":"1259_CR15","unstructured":"National Institute for Health and Care Excellence. Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. Technology appraisal guidance 725. 2021. https:\/\/www.nice.org.uk\/guidance\/TA725. Accessed 21 Dec 2022."},{"key":"1259_CR16","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. 2013. https:\/\/www.nice.org.uk\/process\/pmg9. Accessed 21 Dec 2022."},{"issue":"6","key":"1259_CR17","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s11136-007-9202-8","volume":"16","author":"M Lidgren","year":"2007","unstructured":"Lidgren M, Wilking N, J\u00f6nsson B, Rehnberg C. Health related quality of life in different states of breast cancer. Qual Life Res. 2007;16(6):1073\u201381.","journal-title":"Qual Life Res"},{"issue":"7","key":"1259_CR18","doi-asserted-by":"publisher","first-page":"A749","DOI":"10.1016\/j.jval.2016.09.2297","volume":"19","author":"D Mitra","year":"2016","unstructured":"Mitra D, Wood R, De Courcy J, Iyer S. Patient reported health utility in HR+\/HER2-advanced\/metastatic breast cancer. Value Health. 2016;19(7):A749.","journal-title":"Value Health."},{"key":"1259_CR19","doi-asserted-by":"crossref","unstructured":"Szende A, Janssen B, Cabases J. Self-reported population health: an international perspective based on EQ-5D. Dordrecht (NL): Springer; 2014. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK500356\/. Accessed 21 Dec 2022.","DOI":"10.1007\/978-94-007-7596-1"},{"key":"1259_CR20","unstructured":"National Institute for Health and Care Excellence. Pertuzumab for adjuvant treatment of HER2- positive early stage breast cancer. Technology appraisal guidance 569. 2019. https:\/\/www.nice.org.uk\/guidance\/TA569. Accessed 21 Dec 2022."},{"key":"1259_CR21","unstructured":"National Institute for Health and Care Excellence. Intrabeam radiotherapy system for adjuvant treatment of early breast cancer. Technology appraisal guidance 501. 2018. https:\/\/www.nice.org.uk\/guidance\/ta501. Accessed 21 Dec 2022."},{"key":"1259_CR22","unstructured":"Drugs and pharmaceutical electronic market information tool (eMIT). Department of Health and Social Care; 2018. https:\/\/www.gov.uk\/government\/publications\/drugs-and-pharmaceutical-electronic-market-information-emit. Accessed 21 Dec 2022."},{"key":"1259_CR23","unstructured":"British National Formulary. BMJ Group and Pharmaceutical Press. 2021. https:\/\/bnf.nice.org.uk\/. Accessed 21 Dec 2022."},{"key":"1259_CR24","unstructured":"NHS Improvement, NHS England. National schedule of reference costs\u2014year 2019\/2020 - NHS trust and NHS foundation trusts. 2019. https:\/\/www.england.nhs.uk\/national-cost-collection\/. Accessed 21 Dec 2022."},{"issue":"10","key":"1259_CR25","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1200\/JCO.2016.69.2871","volume":"35","author":"I Smith","year":"2017","unstructured":"Smith I, Yardley D, Burris H, De Boer R, Amadori D, McIntyre K, et al. Comparative efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor-positive, node-positive early breast cancer: final results of the randomized phase III Femara versus Anastrozole Clinical Evaluation (FACE) trial. J Clin Oncol. 2017;35(10):1041\u20138.","journal-title":"J Clin Oncol"},{"key":"1259_CR26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.breast.2021.02.009","volume":"57","author":"EM Salvo","year":"2021","unstructured":"Salvo EM, Ramirez AO, Cueto J, Law EH, Situ A, Cameron C, et al. Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: a systematic review and meta-analysis. The Breast. 2021;57:5\u201317.","journal-title":"The Breast"},{"key":"1259_CR27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.breast.2022.01.012","volume":"62","author":"I Yussof","year":"2022","unstructured":"Yussof I, Tahir NAM, Hatah E, Shah NM. Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: a systematic review. The Breast. 2022;62:22\u201335.","journal-title":"The Breast"},{"key":"1259_CR28","unstructured":"National Institute for Health and Care Excellence. Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence. Technology appraisal guidance TA810. 2022. https:\/\/www.nice.org.uk\/guidance\/ta810. Accessed 21 Dec 2022."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-023-01259-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-023-01259-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-023-01259-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:17:08Z","timestamp":1744715828000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-023-01259-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1259"],"URL":"https:\/\/doi.org\/10.1007\/s40273-023-01259-6","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,23]]},"assertion":[{"value":"23 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The draft of this manuscript was written by Giovany Orozco Leal and all authors had the chance to comment on previous versions of the manuscript. All authors contributed to the study conception and design and all authors were involved with the work of the ERG. Nigel Armstrong acted as project lead, health economist and systematic reviewer on this assessment, critiqued the clinical effectiveness and cost effectiveness methods and evidence, and contributed to the writing of the report. Luke Vale acted as health economic project lead, critiqued the company\u2019s economic evaluation, and contributed to the writing of the report. Giovany Orozco Leal, Diarmuid Coughlan, Tomos Robinson, Asheigh Kernohan and Charlotte Ahmadu acted as health economists on this assessment, critiqued the company\u2019s economic evaluation and contributed to the writing of the report. Susan O\u2019Meara and Kevin McDermott acted as systematic reviewers, critiqued the clinical effectiveness methods and evidence, and contributed to the writing of the report. Steven Duffy critiqued the search methods in the submission and contributed to the writing of the report. Jos Kleijnen critiqued the company\u2019s definition of the decision problem and their description of the underlying health problem and current service provision, contributed to the writing of the report, and supervised the project.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}},{"value":"This project was commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme (NIHR135447). See the HTA programme website for further project information (). This summary of the ERG report was compiled after NICE issued the FAD. The views and opinions expressed herein are those of the authors and do not necessarily reflect those of NICE or the Department of Health.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Giovany Orozco Leal, Nigel Armstrong, Asheigh Kernohan, Charlotte Ahmadu, Diarmuid Coughlan, Kevin McDermott, Steven Duffy, Susan O\u2019Meara, Tomos Robinson, Luke Vale, and Jos Kleijnen have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}